161 related articles for article (PubMed ID: 29137219)
41. The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
Fang R; Xu J; Lin H; Xu X; Tian F
Tumour Biol; 2017 Apr; 39(4):1010428317698356. PubMed ID: 28381185
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of OCT4 induced by modulation of histone marks plays crucial role in breast cancer progression.
Kar S; Patra SK
Gene; 2018 Feb; 643():35-45. PubMed ID: 29203199
[TBL] [Abstract][Full Text] [Related]
43. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
[TBL] [Abstract][Full Text] [Related]
44. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
[TBL] [Abstract][Full Text] [Related]
45. Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A.
Ambrosio S; Saccà CD; Majello B
Biochim Biophys Acta Gene Regul Mech; 2017 Sep; 1860(9):905-910. PubMed ID: 28720390
[TBL] [Abstract][Full Text] [Related]
46. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells.
Zou ZK; Huang YQ; Zou Y; Zheng XK; Ma XD
Int J Mol Med; 2017 Aug; 40(2):319-328. PubMed ID: 28627608
[TBL] [Abstract][Full Text] [Related]
47. A rationally-designed chimeric KDM1A/KDM1B histone demethylase tower domain deletion mutant retaining enzymatic activity.
Burg JM; Makhoul AT; Pemble CW; Link JE; Heller FJ; McCafferty DG
FEBS Lett; 2015 Aug; 589(18):2340-6. PubMed ID: 26226427
[TBL] [Abstract][Full Text] [Related]
48. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents.
Pogribny IP; Tryndyak VP; Pogribna M; Shpyleva S; Surratt G; Gamboa da Costa G; Beland FA
Int J Oncol; 2013 May; 42(5):1822-32. PubMed ID: 23483119
[TBL] [Abstract][Full Text] [Related]
49. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells.
Zhou T; Li Y; Yang L; Liu L; Ju Y; Li C
Oncol Rep; 2017 Jan; 37(1):388-398. PubMed ID: 27878264
[TBL] [Abstract][Full Text] [Related]
50. Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases.
Niwa H; Umehara T
Epigenetics; 2017 May; 12(5):340-352. PubMed ID: 28277979
[TBL] [Abstract][Full Text] [Related]
51. Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells.
Shao G; Wang J; Li Y; Liu X; Xie X; Wan X; Yan M; Jin J; Lin Q; Zhu H; Zhang L; Gong A; Shao Q; Wu C
Sci Rep; 2015 Oct; 5():15344. PubMed ID: 26489763
[TBL] [Abstract][Full Text] [Related]
52. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
53. RING1 and YY1 binding protein suppresses breast cancer growth and metastasis.
Zhou H; Li J; Zhang Z; Ye R; Shao N; Cheang T; Wang S
Int J Oncol; 2016 Dec; 49(6):2442-2452. PubMed ID: 27748911
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of FAD-dependent lysine-specific demethylases by chiral polyamine analogues.
Umezawa N; Tsuji K; Sato S; Kikuchi M; Watanabe H; Horai Y; Yamaguchi M; Hisamatsu Y; Umehara T; Higuchi T
RSC Adv; 2018 Oct; 8(64):36895-36902. PubMed ID: 35558920
[TBL] [Abstract][Full Text] [Related]
55. Targeting LSD2 in breast cancer.
Huang Y; Yin Y; Sun M
Aging (Albany NY); 2018 Jan; 10(1):11-12. PubMed ID: 29356682
[No Abstract] [Full Text] [Related]
56. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Ye Q; Holowatyj A; Wu J; Liu H; Zhang L; Suzuki T; Yang ZQ
Am J Cancer Res; 2015; 5(4):1519-30. PubMed ID: 26101715
[TBL] [Abstract][Full Text] [Related]
57. Structural insight into substrate recognition by histone demethylase LSD2/KDM1b.
Chen F; Yang H; Dong Z; Fang J; Wang P; Zhu T; Gong W; Fang R; Shi YG; Li Z; Xu Y
Cell Res; 2013 Feb; 23(2):306-9. PubMed ID: 23357850
[No Abstract] [Full Text] [Related]
58. Histone Demethylase AMX-1 Regulates Fertility in a p53/CEP-1 Dependent Manner.
Ren X; Tian S; Meng Q; Kim HM
Front Genet; 2022; 13():929716. PubMed ID: 35846143
[TBL] [Abstract][Full Text] [Related]
59. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.
Hou J; Wu J; Dombkowski A; Zhang K; Holowatyj A; Boerner JL; Yang ZQ
Am J Transl Res; 2012; 4(3):247-56. PubMed ID: 22937203
[TBL] [Abstract][Full Text] [Related]
60. HOXB7 Overexpression Leads Triple-Negative Breast Cancer Cells to a Less Aggressive Phenotype.
de Bessa Garcia SA; Araújo M; Pereira T; Freitas R
Biomedicines; 2021 May; 9(5):. PubMed ID: 34063128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
